These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

512 related articles for article (PubMed ID: 33436042)

  • 1. The integration of immune checkpoint inhibitors with VEGF targeted agents in advanced gastric and gastroesophageal adenocarcinoma: a review on the rationale and results of early phase trials.
    Saeed A; Park R; Sun W
    J Hematol Oncol; 2021 Jan; 14(1):13. PubMed ID: 33436042
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities.
    Hack SP; Zhu AX; Wang Y
    Front Immunol; 2020; 11():598877. PubMed ID: 33250900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial.
    Herbst RS; Arkenau HT; Santana-Davila R; Calvo E; Paz-Ares L; Cassier PA; Bendell J; Penel N; Krebs MG; Martin-Liberal J; Isambert N; Soriano A; Wermke M; Cultrera J; Gao L; Widau RC; Mi G; Jin J; Ferry D; Fuchs CS; Petrylak DP; Chau I
    Lancet Oncol; 2019 Aug; 20(8):1109-1123. PubMed ID: 31301962
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pembrolizumab for treatment of advanced gastric and gastroesophageal junction adenocarcinoma.
    Joshi SS; Maron SB; Catenacci DV
    Future Oncol; 2018 Feb; 14(5):417-430. PubMed ID: 29094609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evolution of checkpoint inhibitors for the treatment of metastatic gastric cancers: Current status and future perspectives.
    Taieb J; Moehler M; Boku N; Ajani JA; Yañez Ruiz E; Ryu MH; Guenther S; Chand V; Bang YJ
    Cancer Treat Rev; 2018 May; 66():104-113. PubMed ID: 29730461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of immune-checkpoint inhibitors in metastatic gastric or gastroesophageal junction adenocarcinoma by patient subgroups: A systematic review and meta-analysis.
    Kundel Y; Sternschuss M; Moore A; Perl G; Brenner B; Goldvaser H
    Cancer Med; 2020 Oct; 9(20):7613-7625. PubMed ID: 32869544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II study of cabozantinib and pembrolizumab in advanced gastric/gastroesophageal adenocarcinomas resistant or refractory to immune checkpoint inhibitors.
    Dayyani F; Chao J; Lee FC; Taylor TH; Neumann K; Cho MT
    Oncologist; 2024 Aug; 29(8):721-e1088. PubMed ID: 38823034
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SAFFRON-104: a phase Ib/II study of sitravatinib alone or with tislelizumab in advanced hepatocellular carcinoma and gastric cancer/gastroesophageal junction cancer.
    Li J; Bai Y; Chen Z; Ying J; Guo Y; Fang W; Zhang F; Xiong J; Zhang T; Meng Z; Zhang J; Ren Z; Hao C; Chen Y; Lin X; Pan H; Zhou F; Li X; Yu F; Zhang J; Zhang Z; Qin S
    Cancer Immunol Immunother; 2024 Sep; 73(11):219. PubMed ID: 39235596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy in Gastric Cancer.
    Högner A; Moehler M
    Curr Oncol; 2022 Mar; 29(3):1559-1574. PubMed ID: 35323331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low Programmed Death-Ligand 1-Expressing Subgroup Outcomes of First-Line Immune Checkpoint Inhibitors in Gastric or Esophageal Adenocarcinoma.
    Zhao JJ; Yap DWT; Chan YH; Tan BKJ; Teo CB; Syn NL; Smyth EC; Soon YY; Sundar R
    J Clin Oncol; 2022 Feb; 40(4):392-402. PubMed ID: 34860570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-angiogenic Therapy in Patients with Advanced Gastric and Gastroesophageal Junction Cancer: A Systematic Review.
    Chen LT; Oh DY; Ryu MH; Yeh KH; Yeo W; Carlesi R; Cheng R; Kim J; Orlando M; Kang YK
    Cancer Res Treat; 2017 Oct; 49(4):851-868. PubMed ID: 28052652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiogenesis inhibitors in gastric and gastroesophageal junction cancer.
    Roviello G; Petrioli R; Marano L; Polom K; Marrelli D; Perrella A; Roviello F
    Gastric Cancer; 2016 Jan; 19(1):31-41. PubMed ID: 26329368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of PD-1/PD-L1 inhibitors in gastric or gastro-oesophageal junction cancer based on clinical characteristics: a meta-analysis.
    Huo G; Liu W; Chen P
    BMC Cancer; 2023 Feb; 23(1):143. PubMed ID: 36765356
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ramucirumab and durvalumab for previously treated, advanced non-small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: An open-label, phase Ia/b study (JVDJ).
    Bang YJ; Golan T; Dahan L; Fu S; Moreno V; Park K; Geva R; De Braud F; Wainberg ZA; Reck M; Goff L; Laing N; Mi G; Oliveira JM; Wasserstrom H; Lin CC
    Eur J Cancer; 2020 Sep; 137():272-284. PubMed ID: 32827847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chidamide plus Tyrosine Kinase Inhibitor Remodel the Tumor Immune Microenvironment and Reduce Tumor Progression When Combined with Immune Checkpoint Inhibitor in Naïve and Anti-PD-1 Resistant CT26-Bearing Mice.
    Chen JS; Hsieh YC; Chou CH; Wu YH; Yang MH; Chu SH; Chao YS; Chen CN
    Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
    Xing R; Gao J; Cui Q; Wang Q
    Front Immunol; 2021; 12():783236. PubMed ID: 34899747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ramucirumab for the treatment of gastric or gastro-esophageal junction cancer.
    Khan U; Shah MA
    Expert Opin Biol Ther; 2019 Nov; 19(11):1135-1141. PubMed ID: 31452409
    [No Abstract]   [Full Text] [Related]  

  • 18. Treatment strategy for HER2-negative advanced gastric cancer: salvage-line strategy for advanced gastric cancer.
    Nishida N; Sakai D; Satoh T
    Int J Clin Oncol; 2024 Sep; 29(9):1237-1243. PubMed ID: 38733489
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First Report of Dramatic Tumor Responses with Ramucirumab and Paclitaxel After Progression on Pembrolizumab in Two Cases of Metastatic Gastroesophageal Adenocarcinoma.
    Chakrabarti S; Dong H; Paripati HR; Ross HJ; Yoon HH
    Oncologist; 2018 Jul; 23(7):840-843. PubMed ID: 29674442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cervical cancer - State of the science: From angiogenesis blockade to checkpoint inhibition.
    Minion LE; Tewari KS
    Gynecol Oncol; 2018 Mar; 148(3):609-621. PubMed ID: 29666026
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.